ArticleBMC infectious diseases2025
COVID-19 re-infection: a large cross-sectional population-based study in the northeast of Iran.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToday, COVID-19 reinfection has raised further public health concerns than its primary infection; which make major global health concern that going to the possibility of COVID-19 re-infection, and how strong the body's immunity against this disease in individuals with the previous infection. The present study aimed to investigate the probability of COVID-19 re-infection leading to hospitalization in the population referred to hospitals affiliated with Mashhad University of Medical Sciences, Mashhad, Iran.
methodThe present cross-sectional epidemiological study was conducted on patients referred to hospitals affiliated to the Mashhad University of Medical Sciences, Mashhad, Iran supervision with re-infection of COVID-19 from January 21, 2020, to August 23, 2022. The patients had a definite diagnosis through RT-PCR testing in their first and re-infections, with a time interval of at least one month between the two episodes of infection.
resultsOut of 125,857 patients evaluated, 9,710 (7.7%) were readmitted with COVID-19 infection more than once, with a time interval of more than one month from their previous hospitalization. The average age of hospitalized patients was 54.8 ± 22.97 years, and more than half were men (51.4%). The most common underlying diseases were hypertension (19.4%) and diabetes (14.8%). cardiovascular diseases, asthma, and cancer were the strongest independent risk factors of COVID-19 re-infection (OR = 2.53, 2.47, and 2.36, respectively, p < 0.001 for all cases).
conclusionsIn conclusion, our study demonstrates the importance of understanding the risk factors associated with COVID-19 re-infection and re-hospitalization, particularly in vulnerable populations with comorbidities and substance use disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.